The bill, HB 1772-FN-A, introduces significant changes to the regulation of health care providers, specifically allowing licensed health care providers to administer ibogaine under FDA-approved research protocols, as outlined in the newly inserted section 329:1-i of RSA 329. Additionally, the bill establishes the Physician Associate (PA) Licensure Compact, which is inserted as section 328-D:18-a in RSA 328-D. This compact aims to facilitate the portability of PA licenses across participating states while ensuring patient safety through mutual recognition of licenses, adherence to jurisdictional authority, and the implementation of criminal background checks.

The bill also creates a commission to oversee the PA Licensure Compact, detailing its powers, responsibilities, and governance structure, including the establishment of an executive committee and provisions for public transparency in meetings. It outlines the process for managing adverse actions against PAs, the maintenance of a coordinated data system for licensure records, and the procedures for states to withdraw from the compact. Key provisions include the commission's authority to impose fees, manage finances, and enforce compliance among participating states, while ensuring that existing laws that do not conflict with the compact remain enforceable. The effective date of the act is set for 60 days after passage, with specific provisions for implementation and amendments.

Statutes affected:
Introduced: 6:12
HB1772 text: 6:12